FY2025 · ended Dec 31, 2025 · Revenue $605.49M, +37.1% YoY · Filed Feb 24, 2026
TransMedics Group, Inc. (TMDX) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $605.5 million and net income of $190.3 million. Free cash flow was $133.6 million. As of Jun 30, 2026 it held $472.7 million in cash and investments and $373.7 million in total debt.
Revenue (TTM)
$668.47M
+25.8% vs year-ago TTM
Net income (TTM)
$151.70M
+111.7% vs year-ago TTM
Operating cash flow (TTM)
$145.93M
+26.6% vs year-ago TTM
Free cash flow (TTM)
$79.04M
+355.5% vs year-ago TTM
EPS (TTM)
$3.95
+108.2% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
34.30M
+1.9% vs prior year
Net cash
$98.96M
as of Jun 30, 2026
Operating margin
12.2%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- TMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Andover, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1756262
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
- CapsoVision, Inc CV
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $30.3M |
| Operating income | $108.6M | $37.5M | -$28.7M | -$31.4M | -$39.4M |
| Net income | $190.3M | $35.5M | -$25.0M | -$36.2M | -$44.2M |
| Diluted EPS | $4.87 | $1.01 | -$0.77 | -$1.23 | -$1.60 |
| Operating cash flow | $192.8M | $48.8M | -$13.0M | -$45.8M | -$28.9M |
| Free cash flow | $133.6M | -$80.9M | -$164.9M | -$57.7M | -$32.4M |
| Total assets | $1.1B | $804.1M | $706.0M | $277.1M | $134.9M |
| Total liabilities | $595.3M | $575.5M | $568.8M | $89.8M | $67.0M |
| Stockholders' equity | $473.1M | $228.6M | $137.2M | $187.4M | $67.9M |
| Cash and investments | $488.4M | $336.6M | $394.8M | $201.2M | $92.5M |
| Total debt | $16.9M | $9.0M | $9.7M | $67.6M | $43.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 10, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 21, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
All 628 TransMedics Group, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.